A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: Case report

International Journal of Immunopathology and Pharmacology

Volumn 20, Issue 2, 2007, Pages 401-403

  Autorino, R ^a   Lamendola, M G ^a   De Sio, M ^a   Di Trolio, R A ^b   Ferraraccio, F ^a   Di Lorenzo, Giuseppe ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Biological therapy; Primary lymphoma; Rituximab; Testis cancer

Indexed keywords

CD20 ANTIGEN; CD45 ANTIGEN; KI 67 ANTIGEN; RITUXIMAB;

AGED; ARTICLE; B CELL LYMPHOMA; CANCER RELAPSE; CASE REPORT; CLINICAL FEATURE; DRUG RESPONSE; ECHOGRAPHY; ERYTHEMA; FOLLOW UP; FOOT; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LUNG LYMPH; LYMPH NODE; MALE; MICROSCOPY; NONHODGKIN LYMPHOMA; ORCHIECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCROTUM; TESTIS CANCER; TREATMENT DURATION; TUMOR CELL;

EID: 34547135421     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200702000222     Document Type: Article

References (7)

1. Zucca E., A. Conconi and T. Mughal. 2003. Patterns of outcome and prognostic factors in primary large cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J. Clin. Oncol. 21:20.
2. Shahab N. and D. Doll. 1999. Testicular lymphoma. Semin. Oncol. 26:259.
3. Darby S. and B.W. Hancock. 2005. Localised non-Hodgkin lymphoma of the testis: the Sheffield Lymphoma Group experience. Int. J. Oncol. 26:1093.
4. Doll D. and R. Weiss. 1986. Malignant lymphoma of the testis. Am. J. Med. 81:515.
5. Mazzu D., R. Jeffrey Jr and P. Ralls. 1995. Lymphoma and leukaemia involving the testicles: findings on gray scale and color Doppler sonography. Am. J. Roentgenol. 164:645.
6. Hasselblom S., B. Ridell and H. Wedel. 2004. Testicular lymphoma. A retrospective, population-based, clinical and immunohistochemical study. Acta Oncol. 43:758.
7. McLaughlin P., A.J. Grillo Lopez and B.K. Link. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma. Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:2825.